^
    8d
    BELLWAVE-003: Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (clinicaltrials.gov)
    P2, N=490, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2027 --> Jan 2029 | Trial primary completion date: Mar 2027 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • CD4 (CD4 Molecule)
    |
    TP53 mutation • Chr t(11;14)
    |
    nemtabrutinib (MK-1026)
    10d
    A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015) (clinicaltrials.gov)
    P1, N=16, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    nemtabrutinib (MK-1026)
    24d
    A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022) (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1 trial
    |
    nemtabrutinib (MK-1026)
    1m
    A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). (clinicaltrials.gov)
    P3, N=735, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2035 --> Jul 2035 | Trial primary completion date: Mar 2035 --> Jun 2032
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • BTK (Bruton Tyrosine Kinase) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • IGH mutation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • nemtabrutinib (MK-1026)
    1m
    Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers. (PubMed, Front Oncol)
    Molecular docking studies suggest that nemtabrutinib preferentially binds in the ATP-binding pocket of MEK1. Combined cancer cell panel and biochemical profiling reveals previously underappreciated cross-reactivities of nemtabrutinib indicating a potential application in MAPK-driven cancers.
    Journal
    |
    BRAF (B-raf proto-oncogene) • FGFR3 (Fibroblast growth factor receptor 3) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    BRAF mutation
    |
    nemtabrutinib (MK-1026)
    2ms
    Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype (clinicaltrials.gov)
    P2, N=32, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • nemtabrutinib (MK-1026)
    3ms
    Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Fred Hutchinson Cancer Center
    New P2 trial
    |
    cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • nemtabrutinib (MK-1026)
    3ms
    BELLWAVE-002: A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002) (clinicaltrials.gov)
    P1, N=7, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    nemtabrutinib (MK-1026)
    3ms
    BELLWAVE-001: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (clinicaltrials.gov)
    P1/2, N=190, Active, not recruiting, ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    nemtabrutinib (MK-1026)
    4ms
    waveLINE-006: A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) (clinicaltrials.gov)
    P2, N=223, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Mar 2027 --> Mar 2029
    Trial primary completion date • Pan tumor
    |
    zilovertamab vedotin (MK-2140) • nemtabrutinib (MK-1026)
    5ms
    A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). (clinicaltrials.gov)
    P3, N=720, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2033 --> Mar 2035 | Trial primary completion date: Jun 2033 --> Mar 2035
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • BTK (Bruton Tyrosine Kinase) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • IGH mutation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • nemtabrutinib (MK-1026)
    5ms
    BELLWAVE-002: A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002) (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Merck Sharp & Dohme LLC | N=12 --> 7 | Trial completion date: Mar 2026 --> Aug 2025 | Trial primary completion date: Mar 2026 --> Apr 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    nemtabrutinib (MK-1026)